Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors, announced its participation in two upcoming investor conferences. The company will engage in fireside chats at:
- The H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 11:00 a.m. ET in New York
- The 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 a.m. ET in New York
Webcasts of both events will be available on Sagimet's website, with replays accessible for 90 days after the live events. These conferences provide Sagimet an opportunity to showcase its progress in developing novel therapies targeting dysfunctional metabolic and fibrotic pathways.
Sagimet Biosciences (Nasdaq: SGMT), un'azienda biofarmaceutica in fase clinica che sviluppa inibitori della sintasi degli acidi grassi (FASN), ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda prenderà parte a discussioni informali nei seguenti eventi:
- La 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright il 10 settembre 2024, alle 11:00 ET a New York
- La Conferenza Globale sulla Salute 2024 di Cantor il 17 settembre 2024, alle 9:10 ET a New York
I webcast di entrambi gli eventi saranno disponibili sul sito web di Sagimet, con la possibilità di rivederli per 90 giorni dopo gli eventi dal vivo. Queste conferenze offrono a Sagimet l'opportunità di mostrare i suoi progressi nello sviluppo di nuove terapie mirate a percorsi metabolici e fibrotici disfunzionali.
Sagimet Biosciences (Nasdaq: SGMT), una compañía biofarmacéutica en etapa clínica que desarrolla inhibidores de la sintetasa de ácidos grasos (FASN), anunció su participación en dos próximas conferencias para inversores. La compañía participará en charlas informales en:
- La 26ª Conferencia Anual Global de Inversión de H.C. Wainwright el 10 de septiembre de 2024, a las 11:00 a.m. ET en Nueva York
- La Conferencia Global de Salud 2024 de Cantor el 17 de septiembre de 2024, a las 9:10 a.m. ET en Nueva York
Los webcasts de ambos eventos estarán disponibles en el sitio web de Sagimet, con repeticiones accesibles durante 90 días después de los eventos en vivo. Estas conferencias brindan a Sagimet la oportunidad de mostrar su progreso en el desarrollo de nuevas terapias dirigidas a vías metabólicas y fibróticas disfuncionales.
사기멧 바이오사이언스(Nasdaq: SGMT), 지방산 합성효소(FASN) 억제제를 개발하는 임상 단계의 생명공학 회사는 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 회사는 다음과 같은 불꽃놀이 대화에 참여할 예정입니다:
- H.C. 웨인라이트 제26회 연례 글로벌 투자 회의 2024년 9월 10일 오전 11:00 ET, 뉴욕에서
- 2024 칸토 글로벌 헬스케어 회의 2024년 9월 17일 오전 9:10 ET, 뉴욕에서
두 이벤트의 웹캐스트는 사기멧 웹사이트에서 제공되며, 라이브 이벤트 후 90일 동안 재생할 수 있습니다. 이러한 회의는 사기멧이 기능이상적인 대사 및 섬유화 경로를 표적으로 하는 새로운 치료법 개발에서의 진전을 보여줄 수 있는 기회를 제공합니다.
Sagimet Biosciences (Nasdaq: SGMT), une société bio-pharmaceutique en phase clinique développant des inhibiteurs de la synthase des acides gras (FASN), a annoncé sa participation à deux prochaines conférences pour investisseurs. La société participera à des discussions informelles lors des événements suivants :
- La 26e Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright le 10 septembre 2024, à 11h00 ET à New York
- La Conférence Mondiale sur la Santé 2024 de Cantor le 17 septembre 2024, à 9h10 ET à New York
Les webinaires des deux événements seront disponibles sur le site Web de Sagimet, avec des rediffusions accessibles pendant 90 jours après les événements en direct. Ces conférences offrent à Sagimet l'opportunité de mettre en avant ses avancées dans le développement de nouvelles thérapies ciblant des voies métaboliques et fibrotique dysfonctionnelles.
Sagimet Biosciences (Nasdaq: SGMT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Fettsäuresynthase (FASN)-Hemmer entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird bei folgenden Veranstaltungen in informellen Gesprächen teilnehmen:
- Auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright am 10. September 2024, um 11:00 Uhr ET in New York
- Auf der 2024 Cantor Global Healthcare Conference am 17. September 2024, um 9:10 Uhr ET in New York
Webcasts beider Veranstaltungen sind auf der Website von Sagimet verfügbar, mit Wiederholungen, die 90 Tage nach den Live-Veranstaltungen zugänglich sind. Diese Konferenzen bieten Sagimet die Möglichkeit, seine Fortschritte bei der Entwicklung neuartiger Therapien zur Zielgerichteten Behandlung dysfunktionaler metabolischer und fibrotischer Wege zu präsentieren.
- None.
- None.
SAN MATEO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
- A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York at 11:00 a.m. ET / 8:00 a.m. PT on September 10, 2024; and
- A fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024.
Webcasts of each fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with archived replays available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit www.sagimet.com.
Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at the H.C. Wainwright Global Investment Conference?
What is the date and time of Sagimet Biosciences' (SGMT) fireside chat at the Cantor Global Healthcare Conference?
How long will the webcasts of Sagimet Biosciences' (SGMT) investor conference presentations be available?
What type of inhibitors is Sagimet Biosciences (SGMT) developing?
